References

Aspirin’s History References

  1. Jones R. Nonsteroidal anti-inflammatory drug prescribing: Past, present, and future. Am J Med. 2001; 110:4S.
  2. Mackowiak PA. Brief history of antipyretic therapy. Clin Infect Dis. 2000; 31 Suppl 5:S154.
  3. Mahdi JG, et al. The historical analysis of aspirin discovery, its relation to the willow tree and antiproliferative and anticancer potential. Cell Prolif. 2006; 39:147.
  4. Miner J, Hoffhines A. The discovery of aspirin’s antithrombotic effects. Tex Heart Inst J. 2007; 34:179.
  5. Tiliakos AM, Conn DL. Aspirin: Antiinflammatory drug of choice in 2011? J Rheumatol. 2011; 38:185.

Information about Aspirin References

  1. Berger JS, et al. Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-analysis of randomized controlled trials. JAMA. 2006; 295:306.
  2. De Berardis G, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA. 2012; 307:2286
  3. Rothwell PM, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379:1602.
  4. Veitonmaki T, et al. Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur J Cancer. 2013; 49:938.
  5. Wolff T, et al. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2009; 150:405.

What the Experts Say References

  1. Rothwell PM, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012; 379:1602.
  2. Veitonmaki T, et al. Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur J Cancer. 2013; 49:938.
  3. Wolff T, et al. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2009; 150:405.

Provider References

  1. Maciosek MV, et al. Priorities among effective clinical preventive services. Am J Prev Med. 2006; 31:52.
  2. Wolff T, et al. Aspirin for the primary prevention of cardiovascular events. Ann Intern Med. 2009; 150:405.
  3. De Berardis G, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA. 2012; 307:2286.
  4. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, et al. Aspirin in the primary and secondary prevention of vascular disease. Lancet. 2009; 373:1849.
  5. Hernandez-Diaz S, et al. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med. 2006; 4:22.
  6. Berger JS, et al. Aspirin for the primary prevention of cardiovascular events in women and men. JAMA. 2006; 295:306.
  7. Rothwell PM, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death. Lancet. 2012; 379:1602.
  8. Veitonmaki T, et al. Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur J Cancer. 2013; 49:938.
  9. Chan AT, et al. Aspirin in the chemoprevention of colorectal neoplasia. Cancer Prev Res (Phila). 2012; 5:164.
  10. Kern S, et al. Does low-dose acetylsalicylic acid prevent cognitive decline in women with high cardiovascular risk? BMJ Open. 2012:10.1136/bmjopen-2012-001288.
  11. Partnership for Prevention. Use of High-Value Preventive Care and Lives Saved if Use Improved. Available at http://www.prevent.org/data/files/initiatives/serviceuse%20andlivessaved.pdf. Accessed September 22, 2013.

Policymaker References

  1. Marvasti FM, Stafford RS. From sick care to health care— reengineering prevention into the U.S. system. N Engl J Med. 2012; 367:889.
  2. Partnership for Prevention. Use of High-Value Preventive Care and Lives Saved If Use Improved. Available at http://www.prevent.org/data/files/initiatives/serviceuse%20andlivessaved.pdf

Aspirin Project Research References

  1. Pignone M, et al. Effect of Including Cancer Mortality on the Cost-Effectiveness of Aspirin for Primary Prevention in Men. J Gen Intern Med. 2013; 28:1483.
  2. Stafford RS, et al. An employer-based online tool for providing appropriate aspirin use advice. Prim Prev Insights. 2012; 3:1.

Cancer Prevention: Another Potential Benefit of Low-Dose Aspirin References

  1. Cuzick J, Thorat MA, Bosetti C, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 2015; 26: 47-57.
  2. U.S. Preventive Services Task Force
  3. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 2013; 159: 77-85.
  4. Huang ES, Strate LL, Ho WW, Lee SS, Chan AT. Long-term use of aspirin and the risk of gastrointestinal bleeding. Am J Med 2011; 124: 426- 33.
  5. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009; 302: 649-58.
  6. Ishikawa H, Mutoh M, Suzuki S, et al. The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumors in Asian patients: a randomized trial. Gut 2014; 63:1755-9.
  7. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomized trials. Lancet 2011; 377:31-41.
  8. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009; 302: 649-58.
  9. Coussens LM, Werb Z. Review article inflammation and cancer. Nature 2002; 420: 860-7.
  10. Cancer Facts & Figures 2014
  11. Huang, ES, Strate LL, Ho WW, Lee SS, Chan AT. Long-term use of aspirin and the risk of gastrointestinal bleeding. Am J Med 2011; 124: 426-33.
  12. Gamba CA, Swetter SM, Stefanick ML, et al. Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women. Cancer 2013; 119: 1562-9.
  13. Burn, J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomized controlled trial. Lancet 2011; 378:2081-7.
  14. Baron LA et al. A Randomized Trial of Aspirin to Prevent Colorectal Adenomas. N Engl J Med 2003;348:891-9.
  15. Drew DA et al. Aspirin and colorectal cancer: the promise of precision chemoprevention Nature Reviews/Cancer, March 2016, Vol 16, 173-186.
  16. Chan AT, M.D., Ogino S, Fuchs CS. Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2. NEJM May 24, 2007 vol. 356 no. 21, 2131-2142.